Orgenesis Regenerative Medicine Co. Partners With Belgian MaSTherCell To Manufacture Diabetes Treatment

July 8, 2014 | Israeli company Orgenesis, a leader in the fields of cellular therapy and re-generative medicine, signed an agreement with Belgian company MaSTherCell to produce a treatment for diabetes. The Orgenesis subsidiary in Belgium, Orgenesis SPRL, signed an agreement to scale the manufacturing of insulin-producing liver cells to combat diabetes in preparation for Phase I and Phase II clinical trials. Founded by Israelis but now based in the United States, Orgenesis is a development stage company that seeks to cure Type I Diabetes through cellular therapy and regenerative medicine, a process called ‘trans-differentiation.’